Dr. Martin Baatz is COO and Co-Managing Director at Deep Piction, a Munich-based biotechnology company using AI-driven cell-level imaging technology to accelerate therapeutic development and drug discovery.

Dr. Baatz studied at Yale University and brings over 20 years of experience pioneering computational pathology and digital biomarkers. He previously served as General Manager of Computational Pathology at AstraZeneca in Munich and as Chief Services Officer at Definiens AG, where he built business operations for pharmaceutical partnerships.

Dr. Baatz has published 19 research papers with over 610 citations in image analysis, machine learning, and biomedical imaging. He held senior roles at Panakeia Technologies and BioAI Health, focusing on AI-driven precision medicine.

At Deep Piction, Dr. Baatz helps lead the company's mission to analyze biology at unprecedented cell-level detail in whole organisms, providing insights into drug distribution, toxicity, and efficacy. The platform combines tissue-clearing technology with AI to reduce animal testing and accelerate research.

Dr. Baatz has decades of experience serving pharma customers in clinical and preclinical drug development, scaling businesses, and building high-performance teams across Europe and the US. He is known for his people-centric leadership approach and deep understanding of computational pathology applications.